Showing results (11-20 of 34) with videos related to
Sort By:
Pageof 4
Circulation|February 11, 2004
Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosisDavid R Holmes, Martin B Leon, Jeffrey W Moses, et al.The American Journal of Cardiology|August 28, 2007
Detailed intravascular ultrasound analysis of Zotarolimus-eluting phosphorylcholine-coated cobalt-chromium alloy stent in de novo coronary lesions (results from the ENDEAVOR II trial)Ryota Sakurai, Yoichiro Hongo, Masao Yamasaki, et al.American Heart Journal|August 25, 2009
Association between advanced Killip class at presentation and impaired myocardial perfusion among patients with ST-segment elevation myocardial infarction treated with primary angioplasty and adjunctive glycoprotein IIb-IIIa inhibitorsGiuseppe De Luca, C Michael Gibson, Kurt Huber, et al.The American Journal of Cardiology|February 7, 2015
Impact of time from symptom onset to drug administration on outcome in patients undergoing glycoprotein IIb-IIIa facilitated primary angioplasty (from the EGYPT cooperation)Giuseppe De Luca, Arnoud W J Van't Hof, C Michael Gibson, et al.Journal of Thrombosis and Thrombolysis|November 19, 2009
Impact of distal embolization on myocardial perfusion and survival among patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperationGiuseppe De Luca, C Michael Gibson, Francesco Bellandi, et al.Atherosclerosis|May 12, 2009
Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitorsGiuseppe De Luca, C Michael Gibson, Francesco Bellandi, et al.Journal of Cardiovascular Medicine (Hagerstown, Md.)|March 23, 2013
Impact of time-to-treatment on myocardial perfusion after primary percutaneous coronary intervention with Gp IIb-IIIa inhibitorsGiuseppe De Luca, Michael C Gibson, Arnoud W J Van't Hof, et al.The American Journal of Cardiology|August 6, 2013
Impact of hypertension on distal embolization, myocardial perfusion, and mortality in patients with ST segment elevation myocardial infarction undergoing primary angioplastyGiuseppe De Luca, Arnoud W J van't Hof, Kurt Huber, et al.Journal of Thrombosis and Thrombolysis|March 10, 2010
Gender-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperationGiuseppe De Luca, C Michael Gibson, Mariann Gyöngyösi, et al.Journal of Thrombosis and Thrombolysis|November 26, 2008
Benefits of pharmacological facilitation with glycoprotein IIb-IIIa inhibitors in diabetic patients undergoing primary angioplasty for STEMI. A subanalysis of the EGYPT cooperationGiuseppe De Luca, C Michael Gibson, Francesco Bellandi, et al.Pageof 4